Orphazyme A/S (ORPH) Sinks 54% on CRL

June 18, 2021 6:56 AM EDT
Get Alerts ORPH Hot Sheet
Price: $4.70 -7.84%

Overall Analyst Rating:
    NEUTRAL (Down Down)

Trade Now! 
Join SI Premium – FREE

Get instant alerts when news breaks on your stocks. Claim your 1-week free trial to StreetInsider Premium here.

Orphazyme A/S (NASDAQ: ORPH) sinks 54% in pre-open trading announced it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) following its review of the new drug application for arimoclomol, a heat shock protein amplifier intended for the treatment of Niemann-Pick disease type C (NPC).

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In

Related Categories

FDA, Momentum Movers, Trader Talk

Related Entities

Pre Market Movers, FDA